Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • DIAGNOSIS  (2)
  • 1
    Keywords: RECEPTOR ; tumor ; carcinoma ; CELL ; Germany ; LUNG ; THERAPY ; CT ; DIAGNOSIS ; LUNG-CANCER ; DISEASE ; HISTORY ; liver ; PATIENT ; primary ; prognosis ; tumour ; LYMPH-NODES ; 5-FLUOROURACIL ; NO ; NEOPLASIA ; MALIGNANCIES ; METASTASIS ; metastases ; chemotherapy ; INVOLVEMENT ; SCINTIGRAPHY ; LIVER METASTASES ; SOMATOSTATIN ; POOR-PROGNOSIS ; pancreatic carcinoma ; ETOPOSIDE ; CELL CARCINOMA ; MALIGNANCY ; ENDOCRINE ; EXTRAPULMONARY ; GEMCITABINE ; NODES ; OF-THE-LITERATURE ; pancreas ; review ; small cell carcinoma ; somatostatin-analogue ; UNDIFFERENTIATED CARCINOMA
    Abstract: Small cell carcinoma (SCC) of the pancreas is a rare malignancy with an extremely poor prognosis. We present the case of a 74-year-old man with a 2-month history of upper abdominal discomfort who was diagnosed with SCC of the pancreas tail, involvement of peripancreatic and mesenteric lymph nodes and multiple liver metastases ( extended disease). A CT scan and a positive somatostatin receptor scintigraphy showed no evidence of a primary lung tumour. The diagnosis of a SCC was confirmed by biopsy. Local tumour control could be achieved by gemcitabine once a week and a long-acting somatostatin analogue once a month, but liver metastasis showed progress. Thus, 5-fluorouracil on a weekly basis was started. The patient died 8 months after diagnosis and had not been hospitalised in the meantime. Copyright (C) 2004 S. Karger AG, Basel and IAP
    Type of Publication: Journal article published
    PubMed ID: 15334003
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: SURVIVAL ; carcinoma ; CELL LUNG-CANCER ; COMBINATION ; Germany ; THERAPY ; DIAGNOSIS ; COHORT ; TIME ; PATIENT ; treatment ; chemotherapy ; TISSUE FACTOR ; SAFETY ; pancreatic carcinoma ; RANDOMIZED-TRIAL ; GEMCITABINE ; PHASE-III ; DRUG-DELIVERY ; REGIONAL CHEMOTHERAPY ; pancreatic ; RETROSPECTIVE ANALYSIS ; INTRAARTERIAL CHEMOTHERAPY ; low dose ; retrospective ; ARTERIAL INFUSION ; BLOOD-COAGULATION ; LEUKEMIA GROUP-B ; VITAMIN-K-ANTAGONISTS ; warfarin
    Abstract: Objective. To report the effect of regional combination chemotherapy in a cohort of patients with inoperable pancreatic carcinoma treated with or without low-dose warfarin. Material and methods. A retrospective analysis was performed on 180 patients with pancreatic carcinoma. Patients received one of seven regimens of chemotherapy. Unrelated to the type of chemotherapy, some patients received 1.25 mg warfarin daily. The primary end-point was median survival. Results. Treatment with warfarin resulted in improved median survival from the start of regional therapy ( warfarin versus no warfarin: 5.0 versus 2.3 months, n = 111 versus 69; p 〈 0.0001). This effect was not dependent on the type of chemotherapy used. Among the seven regimens examined, the one consisting of regional gemcitabine and mitomycin-C with systemic gemcitabine was associated with the longest median survival of 5.1 months from the start of regional therapy ( p = 0.006) and 12.7 months from diagnosis. This regimen combined with warfarin was associated with improved median survival ( 7.1 months, n = 32). Conclusions. Treatment with low-dose warfarin improved survival irrespective of the chemotherapy received. Of the regimens examined, the combination of regional gemcitabine and mitomycin-C with systemic gemcitabine was associated with the longest survival time. Survival was increased further by the addition of warfarin. These data provide a rationale, based on safety and efficacy, for a definitive study on the use of warfarin and combined regional and systemic chemotherapy in patients with pancreatic carcinoma
    Type of Publication: Journal article published
    PubMed ID: 16938724
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...